 |
|
|
| |
Timing and Magnitude of Ribavirin Dose Reduction do not impact SVR with Boceprevir + Peginterferon / Ribavirin in the Anemia Management Study in HCV G1 Patients
|
| |
| |
Reported by Jules Levin
AASLD Nov 9-13 2012 Boston
Fred Poordad1, Eric Lawitz2, K. Rajender Reddy3, Nezam Afdhal4, Christophe Hézode5, Stefan Zeuzem6, Samuel S. Lee7, Jose Luis Calleja8, Robert S. Brown, Jr9, Antonio Craxi10, Heiner Wedemeyer11, Bruce R. Bacon12, Steven L. Flamm13, Weiping Deng14, Kenneth Koury14, Frank Dutko14, Margaret Burroughs14, Katia Alves14, Janice Wahl14, Lisa D. Pedicone14*, Clifford Brass14*, Janice Albrecht14*, Mark S. Sulkowski15
1Cedars-Sinai Medical Center, Los Angeles, CA, now at Alamo Medical Research, San Antonio, TX, 2Alamo Medical Research, San Antonio, TX, 3Division of Gastroenterology, University of Pennsylvania, Philadelphia, PA, 4Beth Israel Deaconess Medical Center, Boston, MA, 5Assistance Publique-Hôpitaux de Paris, Henri Mondor Hospital, University of Paris-Est, Créteil, France, 6JW Goethe University Hospital, Frankfurt, Germany, 7University of Calgary, Calgary, Canada, 8Hospital U. Puerta de Hierro, Madrid, Spain, 9Columbia University College of Physicians & Surgeons, New York Presbyterian Hospital, New York, NY, 10University of Palermo, Palermo, Italy, 11Hannover Medical School, Hannover, Germany, 12Saint Louis University School of Medicine, St. Louis, MO, 13Northwestern Feinberg School of Medicine, Chicago, IL, 14Merck Sharp & Dohme Corp., Whitehouse Station, NJ, 15Johns Hopkins University School of Medicine, Baltimore, MD,, *Former employee of Merck Sharp & Dohme Corp., Whitehouse Station, NJ
|
| |
|
|
|
|
|
